Rocket Pharmaceuticals, Inc. reports developments in rare-disease genetic medicines, including its commercial-stage therapy KRESLADI for pediatric patients with severe leukocyte adhesion deficiency-I and its broader pipeline of investigational gene therapies. Company updates commonly address FDA actions, clinical-program progress, regulatory submissions, and financial results tied to research, development, and commercial readiness.
Recurring news themes include the AAV cardiovascular portfolio, such as RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy, and RP-A701 for BAG3-related dilated cardiomyopathy. Rocket also reports capital and balance-sheet actions, including monetization of its Rare Pediatric Disease Priority Review Voucher, as well as presentations at healthcare conferences.
Rocket Pharmaceuticals (NASDAQ: RCKT) will participate in a panel at Chardan’s 10th Annual Healthcare Conference on October 20, 2026. The panel is scheduled for 11:30 AM ET, and the company will also host investor meetings.
Rocket Pharmaceuticals (RCKT) outlined its FDA-aligned pivotal Phase 2 trial for RP-A501 in Danon disease and updated clinical efficacy and safety findings. The efficacy population comprises 12 males receiving commercial-grade therapy at a recalibrated dose, including the first three treated under the modified protocol. Success requires at least seven patients at 12 months to show myocardial LAMP2 protein expression of at least Grade 1 and at least a 10% reduction in left ventricular mass index, a measure of heart muscle mass.
The first three completed initial observation without evidence of two specified safety complications; findings remain preliminary. Original-dose safety findings included a fatal serious adverse reaction. Phase 1 follow-up showed heart muscle mass below baseline in five of six patients at approximately three to seven years. Rocket expects dosing completion by mid-2027 and topline results in mid-2028.
Rocket Pharmaceuticals (RCKT) entered a credit facility agreement with Hercules Capital (HTGC) for up to $150 million to support cardiovascular development. Rocket received $35 million at closing and may draw another $35 million during specified periods, subject to agreement terms. Another $30 million depends on a Danon clinical milestone; $50 million requires Hercules’ investment committee approval.
The facility has an initial 30-month interest-only period, a 48-month maturity and milestone-dependent extensions. It also includes warrants to purchase Rocket common stock. Rocket expects its existing resources plus the initial funding to support operations into the third quarter of 2028. Further borrowing could extend its runway into 2029, depending on borrowing conditions, draw timing and amounts, and operating expenditures.
Rocket Pharmaceuticals (RCKT)/b) announced FDA alignment on the pivotal Phase 2 trial design for RP-A501 in Danon disease, including a 12-patient efficacy population and established 12‑month co-primary endpoints.The FDA reviewed initial safety data from the first three patients treated under a modified protocol at a recalibrated RP-A501 dose of 3.8 × 10¹³ GC/kg. All three completed at least four weeks of follow-up, were discharged after observation, and showed no clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome. Based on these data, the FDA confirmed continued enrollment and dosing under the modified protocol and that these first three patients count toward the 12-patient pivotal population, leaving nine to enroll. The 12‑month co-primary endpoints are myocardial LAMP2 expression and a 10% reduction from baseline in left ventricular mass index, which are intended to support a potential accelerated approval pathway.
Rocket Pharmaceuticals (RCKT) will participate in the 2026 Cantor Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference in New York.
CEO Gaurav Shah will join fireside chats and management will host investor meetings. The Cantor event is on September 10, 2026 at 1:00 PM ET, and the Morgan Stanley event is on September 15, 2026 at 9:15 AM ET. Webcasts will be available in the Investors section of the company’s website.
Rocket Pharmaceuticals (NASDAQ: RCKT) reported second quarter 2026 results highlighted by FDA accelerated approval of KRESLADI for severe LAD-I and monetization of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $180 million in non-dilutive capital.
For the quarter ended June 30, 2026, cash, cash equivalents and investments were $283.7 million, with an expected cash runway into the second quarter of 2028. Rocket reported net income of $123.2 million, or $1.09 basic EPS, versus a $68.9 million net loss a year earlier. R&D expenses fell to $29.5 million from $42.7 million, and G&A to $17.4 million from $25.0 million. Pipeline updates included favorable initial RP-A501 safety observations in Danon disease, continued FDA engagement and Phase 1 enrollment for RP-A601 in PKP2-ACM, planned 2026 Phase 1 initiation for RP-A701 in BAG3-DCM, and preparations for KRESLADI commercial availability and patient onboarding in Q4 2026.
Rocket Pharmaceuticals (NASDAQ: RCKT) reported a positive safety update from the initial three patients treated with gene therapy RP-A501 under a modified protocol in its global, pivotal Phase 2 Danon disease trial. Patients received a recalibrated single dose of 3.8 × 10¹³ GC/kg plus a refined immunomodulatory regimen of rituximab, sirolimus and corticosteroids, administered sequentially with at least four weeks between infusions.
According to Rocket Pharmaceuticals, no thrombotic microangiopathy, capillary leak syndrome or other significant safety concerns have been seen in these patients so far. The 12‑patient, single‑arm Phase 2 trial remains pivotal, and the company is actively engaging with the U.S. FDA to align on dosing additional patients and completing the trial, with a regulatory pathway update and a broader Danon disease program update expected in the second half of 2026.
Rocket Pharmaceuticals (NASDAQ:RCKT) closed the sale of its FDA-granted Rare Pediatric Disease Priority Review Voucher for $180 million in gross proceeds.
The voucher was awarded after March 2026 approval of KRESLADI for LAD-I. Pro forma cash rose from $144.4 million to about $322.6 million, which Rocket expects will fund operations into Q2 2028.
Rocket Pharmaceuticals (NASDAQ:RCKT) will participate in two upcoming healthcare investor conferences in June 2026. CEO Gaurav Shah, M.D., will join fireside chats and management will host investor meetings at both events.
Live webcasts will be accessible via the Investors section of the company’s website.
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q1 2026 results and operational updates on May 7, 2026. Key items: KRESLADI received FDA accelerated approval for severe LAD-I, the company monetized a $180 million PRV, pro forma cash is ~$322.6M, and dosing resumed in the pivotal Phase 2 RP-A501 Danon study.
Rocket expects cash runway into Q2 2028 and plans a Danon program update in H2 2026; first patient dosing for RP-A701 is anticipated mid-2026.